Association Between Genetic Polymorphisms in the Prostaglandin Pathway and the Development of Patent Ductus Arteriosus in Preterm Infants
Preprint
- 13 August 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Patent ductus arteriosus (PDA) constitutes a significant clinical condition, frequently associated with a spectrum of complications that may profoundly compromise the health status of neonates, particularly those born preterm. Multiple predisposing factors—including prematurity, low birth weight, and respiratory insufficiency—have been consistently documented in the scientific literature. In this study, we investigated the influence of genetic polymorphisms in genes associated with the arachidonic acid–prostaglandin metabolic pathway. Specifically, we analyzed variants in genes encoding phospholipase A2 (rs10798059, rs1549637, rs4375, rs1805017, rs1051931), cyclooxygenase-1 (rs1236913), prostaglandin synthase 2 (rs13283456), and the prostaglandin E2 receptor EP4 (rs4613763). The study cohort comprised 99 preterm neonates born between 24 and 32 weeks of gestation. Genetic analyses were performed to identify polymorphisms in the aforementioned genes. Statistical evaluation demonstrated that selected polymorphic variants were significantly associated with an increased risk of patent ductus arteriosus development. This study represents a preliminary step toward elucidating the contribution of genetic variability to the pathogenesis of patent ductus arteriosus. Improved understanding of these molecular mechanisms may facilitate the early identification of neonates at increased risk and support the implementation of targeted monitoring and preventive strategies in this high-risk population.Keywords
All Related Versions
This publication has 16 references indexed in Scilit:
- Understanding the pathobiology in patent ductus arteriosus in prematurity—beyond prostaglandins and oxygenPediatric Research, 2019
- The ductus arteriosus: Physiology, regulation, and functional and congenital anomaliesArchives of Cardiovascular Diseases, 2011
- Mechanisms Regulating the Ductus ArteriosusNeonatology, 2006
- Finding genetic contributions to sporadic disease: A recessive locus at 12q24 commonly contributes to patent ductus arteriosusProceedings of the National Academy of Sciences, 2002
- Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosusNature Medicine, 2002
- Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2Proceedings of the National Academy of Sciences, 2001
- Coordinated regulation of fetal and maternal prostaglandins directs successful birth and postnatal adaptation in the mouseProceedings of the National Academy of Sciences, 2000
- The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birthNature, 1997
- Histologic studies on normal and persistent ductus arteriosus in the dogJACC, 1985
- Control of the ductus arteriosusPhysiological Reviews, 1975